Hallucinogens and Serotonin 5-HT2A Receptor-Mediated Signaling Pathways
Juan F López-Giménez, Javier González-Maeso
Current Topics in Behavioral Neurosciences 2017 DOI: 10.1007/7854_2017_478 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | LSD Mescaline Psilocybin Serotonin |
| Keywords | Hallucinogen 5-HT Receptor 5-ht2 receptor Agonist Pharmacology |
| Citations | 302 |
| Key findings | Several effects of hallucinogens involve agonist activity at the serotonin 5-HT2A receptor. |
Abstract
The neuropsychological effects of naturally occurring psychoactive chemicals have been recognized for millennia. Hallucinogens, which include naturally occurring chemicals such as mescaline and psilocybin, as well as synthetic compounds, such as lysergic acid diethylamide (LSD), induce profound alterations of human consciousness, emotion, and cognition. The discovery of the hallucinogenic effects of LSD and the observations that LSD and the endogenous ligand serotonin share chemical and pharmacological profiles led to the suggestion that biogenic amines like serotonin were involved in the psychosis of mental disorders such as schizophrenia. Although they bind other G protein-coupled receptor (GPCR) subtypes, studies indicate that several effects of hallucinogens involve agonist activity at the serotonin 5-HT2A receptor. In this chapter, we review recent advances in understanding hallucinogen drug action through characterization of structure, neuroanatomical location, and function of the 5-HT2A receptor.
In the evidence
This study is part of the evidence base for a synthesis in the library. Here is how each one recorded it.
-
State of the evidence: Mescaline Supports
Several effects of hallucinogens including mescaline involve agonist activity at the serotonin 5-HT2A receptor.
Synthesized
Comparable studies
Other narrative reviews on serotonin, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Serotonin research: contributions to understanding psychoses | 2008 | Review | |
| Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research | 2001 | Review | |
| 3,4‐Methylenedioxymethamphetamine (MDMA, “Ecstasy”): pharmacology and toxicology in animals and humans | 1994 | Review | |
| (±)3,4-Methylenedioxymethamphetamine (‘Ecstasy’)-Induced Serotonin Neurotoxicity: Studies in Animals | 2000 | Review | |
| Psychedelics as anti-inflammatory agents Animal models and cellular studies | 2018 | Review |
Citations in the library
Cited by 191
- Towards an understanding of psychedelic-induced neuroplasticity. Neuropsychopharmacology 2023
- The effects of microdose LSD on time perception: a randomised, double-blind, placebo-controlled trial Psychopharmacology November 26, 2018
- Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression CNS Drugs November 17, 2021
- Transcriptional regulation in the rat prefrontal cortex and hippocampus after a single administration of psilocybin Journal of Psychopharmacology November 4, 2020
- Biochemical Mechanisms Underlying Psychedelic-Induced Neuroplasticity. Biochemistry January 21, 2022
and 186 more in the library
Cites 41
- Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action Neuroreport December 1, 1998
- Safety, Tolerability, and Efficacy of Psilocybin in 9 Patients With Obsessive-Compulsive Disorder The Journal of Clinical Psychiatry November 15, 2006
- Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sciences December 17, 1984
- Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials Journal of Psychopharmacology March 8, 2012
- 5-HT2AReceptor-Mediated Regulation of Brain-Derived Neurotrophic Factor mRNA in the Hippocampus and the Neocortex Journal of Neuroscience April 15, 1997
and 36 more in the library